Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics (OTCQB:RLFTY) has published its 2025 half-year report, highlighting progress in its pharmaceutical pipeline. The company received Rare Pediatric Disease designation for RLF-TD011 in epidermolysis bullosa and held a successful pre-IND meeting with the FDA.
Relief is advancing RLF-OD032, a next-generation liquid sapropterin formulation for phenylketonuria, with a pivotal trial expected to commence this quarter. The company's cash position is projected to sustain operations into late 2026, extending beyond the planned regulatory submission for RLF-OD032 in the United States. Additionally, Relief is pursuing a business combination with NeuroX to establish an AI-driven health tech company.
Relief Therapeutics (OTCQB:RLFTY) ha pubblicato il rapporto semestrale 2025, evidenziando i progressi nel suo portafoglio farmaceutico. La società ha ottenuto la designazione per malattia pediatrica rara per RLF-TD011 nell'epidermolisi bollosa e ha tenuto un incontro pre-IND di successo con la FDA.
Relief sta sviluppando RLF-OD032, una formulazione liquida di sapropterina di nuova generazione per la fenilchetonuria, con uno studio pivotale previsto per l'avvio nel corso di questo trimestre. La posizione di cassa della società dovrebbe sostenere le operazioni fino alla fine del 2026, oltre la prevista sottomissione regolatoria per RLF-OD032 negli Stati Uniti. Inoltre, Relief sta perseguendo una combinazione aziendale con NeuroX per creare una società health tech basata sull'intelligenza artificiale.
Relief Therapeutics (OTCQB:RLFTY) ha publicado su informe semestral 2025, destacando avances en su cartera farmacéutica. La compañía recibió la designación de enfermedad pediátrica rara para RLF-TD011 en epidermólisis bullosa y mantuvo una reunión pre-IND exitosa con la FDA.
Relief está avanzando con RLF-OD032, una formulación líquida de sapropterina de nueva generación para la fenilcetonuria, con un ensayo pivotal que se espera comience este trimestre. La posición de caja de la compañía se proyecta que sostendrá las operaciones hasta finales de 2026, más allá de la prevista presentación regulatoria de RLF-OD032 en Estados Unidos. Además, Relief busca una combinación empresarial con NeuroX para establecer una compañía health tech impulsada por IA.
Relief Therapeutics (OTCQB:RLFTY)는 2025년 반기보고서를 발표하며 의약품 파이프라인의 진전을 강조했습니다. 회사는 RLF-TD011에 대해 희귀 소아 질환 지정(Rare Pediatric Disease)을 받았고 FDA와의 사전 IND(Pre-IND) 미팅을 성공적으로 진행했습니다.
Relief는 페닐케톤뇨증 치료를 위한 차세대 액상 사프로프테린 제형인 RLF-OD032를 개발 중이며, 이 분기 중 중추적(pivotal) 임상이 시작될 것으로 예상됩니다. 회사의 현금 보유는 2026년 말까지 운영을 유지할 것으로 전망되며, 이는 미국에서의 RLF-OD032 규제 제출 시점을 넘어서는 수준입니다. 또한 Relief는 NeuroX와의 기업 결합을 추진해 AI 기반 헬스테크 회사를 설립하려 하고 있습니다.
Relief Therapeutics (OTCQB:RLFTY) a publié son rapport semestriel 2025, soulignant les avancées de sa pipeline pharmaceutique. La société a obtenu la désignation de maladie pédiatrique rare pour RLF-TD011 dans l'épidermolyse bulleuse et a tenu une réunion pré‑IND réussie avec la FDA.
Relief fait progresser RLF-OD032, une formulation liquide de sapropterine de nouvelle génération pour la phénylcétonurie, et un essai pivotal devrait débuter ce trimestre. La trésorerie de la société devrait permettre de couvrir les opérations jusqu'à la fin de 2026, au‑delà du dépôt réglementaire prévu pour RLF-OD032 aux États‑Unis. De plus, Relief poursuit une combinaison d'entreprises avec NeuroX pour créer une société health tech pilotée par l'IA.
Relief Therapeutics (OTCQB:RLFTY) hat seinen Halbjahresbericht 2025 veröffentlicht und Fortschritte in seiner Arzneimittelpipeline hervorgehoben. Das Unternehmen erhielt die Einstufung als Rare Pediatric Disease für RLF-TD011 bei Epidermolysis bullosa und führte ein erfolgreiches Pre-IND-Meeting mit der FDA durch.
Relief treibt RLF-OD032 voran, eine neuartige flüssige Sapropterin-Formulierung für Phenylketonurie, für die voraussichtlich in diesem Quartal eine pivotal Studie beginnen wird. Die Liquiditätslage des Unternehmens sollte den Geschäftsbetrieb bis Ende 2026 sichern und damit über die geplante regulatorische Einreichung für RLF-OD032 in den USA hinausreichen. Zusätzlich strebt Relief eine Unternehmenszusammenführung mit NeuroX an, um ein KI-getriebenes Health‑Tech-Unternehmen zu gründen.
- Rare Pediatric Disease designation received for RLF-TD011
- Strong cash position funding operations through late 2026
- Pivotal trial for RLF-OD032 starting this quarter
- Strategic expansion into AI health tech through NeuroX merger
- None.
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update.
"Relief continued to make steady progress across our pipeline and corporate initiatives," said Dr. Raghuram Selvaraju, chairman of the board of directors. "We advanced RLF‑TD011, our lead wound care candidate, with the receipt of Rare Pediatric Disease designation for epidermolysis bullosa and a productive Type B pre‑IND meeting with the FDA. We also progressed RLF‑OD032, our next‑generation liquid sapropterin formulation for phenylketonuria, toward a pivotal trial expected to begin this quarter. Our focus remains on advancing our core programs, with existing cash reserves projected to fund operations into at least late 2026, beyond the targeted regulatory submission of RLF‑OD032 for approval in the United States. In parallel, we are taking steps to establish a scalable, AI-driven health tech company through the proposed business combination with NeuroX."
The report, available on the Company's website , includes interim financial statements for the six months ended June 30, 2025, and a shareholder update.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. In particular, there can be no assurance that the proposed business combination with NeuroX will be completed, as it remains subject to the execution of a definitive agreement, completion of satisfactory due diligence, and other conditions. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What major developments did Relief Therapeutics (RLFTY) announce in its 2025 half-year report?
How long will Relief Therapeutics' current cash reserves last?
What is Relief Therapeutics' plan for RLF-OD032?
What strategic business combination is Relief Therapeutics pursuing in 2025?
